Nadav Kidron

We're doing both, the American FDA and the Chinese FDA.

With the American FDA, we're now doing another study that will take us into a phase three, which is the last trial you need to do in order to register the drug.

And with the Chinese FDA, we're probably going to get to the market even before the United States.

So we got $30 million out of the 50.

We should be getting a few more millions this year and some of it earlier next year as well.

No, we raised.

The company today is a public company on NASDAQ.

The company, just the cash the company has today, it's about $50 million, 5-0, and there's more cash coming from the Chinese.

Up to today, altogether, I would say probably over $100 million of money between the revenues and money was raised, went into the company.

So it's a real interesting enterprise.

Why do you go?

2013, we went up to NASDAQ.

Well, you're smart enough to be in the software world because in our world, it takes a lot of money and a huge investment in a lot of time before you see anything.

So when you go to an investor, I come to you and I say, listen, you know, do you want to invest in something that can make the lives of many people better, but you may have to sit on the sideline for 10 years.

They can say, ah, you know what?

I don't want to lock my money for 10 years.

So there's many, many, many, many companies who are doing R&D within pharma that they went public because people are willing to take the risk and the downside and the upside, but they also want to have the liquidity.

So if for some reason they want to get out, they can get out.

If the company has reached a milestone, even though it hasn't reached the full registration, you know, hopefully share price will go up and they can make their bucks, their profit and take it off the table.

So it's a very difficult area to manage.